These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 3138274)

  • 1. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide.
    Rittmaster RS
    J Clin Endocrinol Metab; 1988 Oct; 67(4):651-5. PubMed ID: 3138274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS; Thompson DL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
    Andreyko JL; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response effect of depot leuprolide acetate on serum androgens in hirsute women.
    Rittmaster RS; Arab DM; Lehman L
    Fertil Steril; 1996 May; 65(5):912-5. PubMed ID: 8612847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
    Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.
    Azziz R; Ochoa TM; Bradley EL; Potter HD; Boots LR
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3406-11. PubMed ID: 8530573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity affects circulating estradiol levels of premenopausal hirsute women receiving leuprolide acetate depot.
    Dumesic DA; Matteri RL
    Int J Fertil Menopausal Stud; 1993; 38(3):139-46. PubMed ID: 8348161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study.
    Rosenfield RL; Perovic N; Ehrmann DA; Barnes RB
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3408-11. PubMed ID: 8784105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism.
    Bertoli A; Fusco A; Magnani A; Marini MA; Di Daniele N; Gatti S; Lauro R
    Exp Clin Endocrinol Diabetes; 1995; 103(1):15-20. PubMed ID: 7621099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism.
    Elkind-Hirsch KE; Anania C; Mack M; Malinak R
    Fertil Steril; 1995 May; 63(5):970-8. PubMed ID: 7720941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism.
    Bayhan G; Bahçeci M; Demirkol T; Ertem M; Yalinkaya A; Erden AC
    Clin Exp Obstet Gynecol; 2000; 27(3-4):203-6. PubMed ID: 11214952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism.
    Tiitinen A; Simberg N; Stenman UH; Ylikorkala O
    J Clin Endocrinol Metab; 1994 Aug; 79(2):447-51. PubMed ID: 8045961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men.
    Behre HM; Kliesch S; Pühse G; Reissmann T; Nieschlag E
    J Clin Endocrinol Metab; 1997 May; 82(5):1403-8. PubMed ID: 9141524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androsterone glucuronide is a marker of adrenal hyperandrogenism in hirsute women.
    Thompson DL; Horton N; Rittmaster RS
    Clin Endocrinol (Oxf); 1990 Mar; 32(3):283-92. PubMed ID: 2160872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of prostate-specific antigen and androgens after nasal administration of a gonadotropin releasing hormone-agonist in hirsute women.
    Kocak M; Tarcan A; Beydilli G; Koç S; Haberal A
    Gynecol Endocrinol; 2004 Apr; 18(4):179-85. PubMed ID: 15293888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.